The global Cancer Vaccines Market is expected to garner a market value of US$ 9 Billion in 2023 and is expected to accumulate a market value of US$ 24.22 Billion by registering a CAGR of 12% in the forecast period 2023 to 2033. The market for Cancer Vaccines registered a CAGR of 9% in the historical period 2018 to 2022.
The Cancer Vaccines market is a segment of the healthcare industry that deals with the effective management of the condition. The Cancer Vaccines market offers a range of vaccines that uses the body's own immune system to recognize and attack cancer cells. There are two main types of cancer vaccines: preventive vaccines and therapeutic vaccines. Preventive vaccines are designed to prevent certain types of cancer, such as the HPV vaccine that helps prevent cervical cancer. Therapeutic vaccines, on the other hand, are designed to treat cancer by stimulating the immune system to recognize and attack cancer cells.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 9 Billion |
| Anticipated Forecast Value (2033) | US$ 24.22 Billion |
| Projected Growth Rate (2023 to 2033) | 12% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Cancer Vaccines reflected a value of 9% during the historical period, 2018 to 2022. During this period, the demand for treatment for Cancer increased, driven by factors such as increasing incidence of cancer, growing awareness about cancer prevention and treatment, and technological advancements in vaccine development.
Looking ahead to the period from 2023 to 2033, the cancer vaccines market is expected to continue growing, although at a slightly slower pace than in the previous period. Cancer is expected to remain a major health concern globally, which will drive demand for cancer vaccines. In recent years, several new cancer vaccine options have emerged for Cancer, pushing the market for Cancer Vaccines is expected to register a CAGR of 12% in the forecast period 2023 to 2033.
Growing advancements in diagnostic and treatment options to push the market growth
The Cancer Vaccines Market is expected to experience significant growth in the coming years, driven by several factors. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018. The most common types of cancer worldwide include lung, breast, colorectal, prostate, stomach, and liver cancer.
The increasing prevalence of cancer has led to the development of new technologies such as gene editing and personalized medicine is enabling the development of more effective cancer vaccines. The prevalence of cancer varies by region and demographic group. Low- and middle-income countries are disproportionately affected by cancer, with over 60% of new cancer cases and 70% of cancer deaths occurring in these countries. This is due to a combination of factors including lack of access to prevention and early detection services, limited resources for cancer vaccine, and higher rates of risk factors such as tobacco use and infectious diseases.
Cancer is a major public health concern globally, with millions of new cases diagnosed each year. Overall, the prevalence of cancer is expected to continue to increase globally, with an estimated 29.5 million new cancer cases and 16.5 million cancer deaths expected by 2040, according to the International Agency for Research on Cancer (IARC). The combination of these factors is expected to drive significant growth in the Cancer vaccines market in the coming years.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
Cancer is a complex disease, and its nature differs from person to person. As a result, developing a vaccine that can effectively treat all forms of cancer is a major challenge. The current cancer vaccines on the market have limited success rates, and there is a need to develop more effective vaccines to meet the growing demand for cancer treatment.
Many people are not aware of the benefits of cancer vaccines, and this can limit their adoption and use. Furthermore, regulatory challenges can limit the development and approval of new vaccines for Cancer, which can slow down progress in the field. Some people may be resistant to vaccines, and this can limit the effectiveness of cancer vaccines.
Increasing Advancements in the Diagnostic Techniques Shaping Landscape for Cancer Vaccines in South & East Asia
The Cancer Vaccines Market in the South and East Asia region is growing, driven by several factors such as increasing cancer incidence, growing awareness about cancer prevention, and the rising demand for personalized medicine are driving the growth of the cancer vaccine market in the region. Additionally, the increasing adoption of advanced technologies such as Next-generation sequencing (NGS) data analysis and bioinformatics in cancer research is expected to further fuel market growth.
In South and East Asia, the Cancer Vaccines Market is expected to witness significant growth in the coming years, driven by factors such as increasing cancer incidence, growing demand for innovative treatment options, and rising investments in cancer research and development.
In addition, there is a growing awareness about the disease in the region, which is leading to more frequent diagnoses and better access to vaccines. Governments and healthcare organizations are also taking steps to improve the diagnosis and treatment of Cancer, which is helping to drive growth in the market.
Increasing Focus on Technological advancements Shaping Landscape for Cancer Vaccines in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. As awareness about cancer vaccines increases among the general population, more people are opting for these vaccines as a preventive measure against cancer. North America has some of the world's leading research institutions, which are dedicated to developing new and effective cancer vaccines. This has led to the development of several innovative cancer vaccines in recent years.
Additionally, The regulatory environment for cancer vaccines in North America is favorable, with regulatory agencies such as the FDA in the USA providing fast-track approval for promising cancer vaccines. Healthcare expenditure in the region is increasing, which has led to increased investment in cancer treatment and prevention, including cancer vaccines.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Recombinant cancer vaccines segment to hold a significant share and push market growth
Currently, the recombinant cancer vaccines segment is expected to account for a significant share of the market. Recombinant cancer vaccines are developed using genetic engineering technology, which enables the production of specific proteins that can stimulate the immune system to attack cancer cells. This technology has shown promising results in clinical trials and has been approved for use in the treatment of certain types of cancer, such as prostate cancer and melanoma.
Therapeutic cancer vaccines to take the lead and drive market growth
Currently, the therapeutic cancer vaccines segment is expected to account for a significant share of the market. Therapeutic cancer vaccines are designed to stimulate the immune system to attack existing cancer cells in patients who have already been diagnosed with cancer. These vaccines are being developed for a variety of cancer types and have shown promising results in clinical trials.
Key players in the market include companies such as Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Vaccinogen, Inc., F Hoffmann-La Roche AG, and OSE Immunotherapeutics, along with healthcare providers and technology companies among other global players.
The firm developed one of the most widely-distributed Covid-19 vaccines in collaboration with USA pharmaceutical firm Pfizer. The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 9 Billion |
| Market Value in 2033 | US$ 24.22 Billion |
| Growth Rate | CAGR of 12% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc, Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Vaccinogen, Inc., F Hoffmann-La Roche AG, and OSE Immunotherapeutics |
| Customization | Available Upon Request |
From 2018 to 2022, the Cancer Vaccines Market grew at a CAGR of 9%.
The global Cancer Vaccines Market is expected to grow with a 12% CAGR during 2023 to 2033.
As of 2033, the Cancer Vaccines Market is expected to reach US$ 24.22 Billion
According to the FMI analysis, the recombinant cancer vaccines segment accounts for the largest market share.
North America is expected to possess 40% market share for the Cancer Vaccines Market.
The Asia Pacific market is projected to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
The market is expected to record a 12% CAGR throughout 2033.
Innovations in diagnostics and treatment options are likely to grow the market.
Recombinant cancer vaccines to dominate the market.
North America to acquire a 40% share during the forecast period.
The market is expected to accumulate a value of US$ 24.22 billion by 2033.
1. Executive Summary | Cancer Vaccines Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Technology, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Technology, 2023 to 2033
5.3.1. Recombinant Cancer Vaccines
5.3.2. Whole-cell Cancer Vaccines
5.3.3. Viral Vector & DNA Cancer Vaccines
5.3.4. Antigen/Adjuvant Cancer Vaccines
5.4. Y-o-Y Growth Trend Analysis By Technology, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Method
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Method, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Method, 2023 to 2033
6.3.1. Preventive Vaccine
6.3.2. Therapeutic Vaccine
6.4. Y-o-Y Growth Trend Analysis By Treatment Method, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment Method, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033
7.3.1. Prostate Cancer
7.3.2. Cervical Cancer
7.3.3. Other Applications
7.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Technology
9.2.3. By Treatment Method
9.2.4. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Technology
9.3.3. By Treatment Method
9.3.4. By Application
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Technology
10.2.3. By Treatment Method
10.2.4. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Technology
10.3.3. By Treatment Method
10.3.4. By Application
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Technology
11.2.3. By Treatment Method
11.2.4. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Technology
11.3.3. By Treatment Method
11.3.4. By Application
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Technology
12.2.3. By Treatment Method
12.2.4. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Technology
12.3.3. By Treatment Method
12.3.4. By Application
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Technology
13.2.3. By Treatment Method
13.2.4. By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Technology
13.3.3. By Treatment Method
13.3.4. By Application
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Technology
14.2.3. By Treatment Method
14.2.4. By Application
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Technology
14.3.3. By Treatment Method
14.3.4. By Application
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Technology
15.2.3. By Treatment Method
15.2.4. By Application
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Technology
15.3.3. By Treatment Method
15.3.4. By Application
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Technology
16.1.2.2. By Treatment Method
16.1.2.3. By Application
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Technology
16.2.2.2. By Treatment Method
16.2.2.3. By Application
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Technology
16.3.2.2. By Treatment Method
16.3.2.3. By Application
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Technology
16.4.2.2. By Treatment Method
16.4.2.3. By Application
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Technology
16.5.2.2. By Treatment Method
16.5.2.3. By Application
16.6. United kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Technology
16.6.2.2. By Treatment Method
16.6.2.3. By Application
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Technology
16.7.2.2. By Treatment Method
16.7.2.3. By Application
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Technology
16.8.2.2. By Treatment Method
16.8.2.3. By Application
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Technology
16.9.2.2. By Treatment Method
16.9.2.3. By Application
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Technology
16.10.2.2. By Treatment Method
16.10.2.3. By Application
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Technology
16.11.2.2. By Treatment Method
16.11.2.3. By Application
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Technology
16.12.2.2. By Treatment Method
16.12.2.3. By Application
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Technology
16.13.2.2. By Treatment Method
16.13.2.3. By Application
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Technology
16.14.2.2. By Treatment Method
16.14.2.3. By Application
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Technology
16.15.2.2. By Treatment Method
16.15.2.3. By Application
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Technology
16.16.2.2. By Treatment Method
16.16.2.3. By Application
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Technology
16.17.2.2. By Treatment Method
16.17.2.3. By Application
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Technology
16.18.2.2. By Treatment Method
16.18.2.3. By Application
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Technology
16.19.2.2. By Treatment Method
16.19.2.3. By Application
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Technology
16.20.2.2. By Treatment Method
16.20.2.3. By Application
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Technology
16.21.2.2. By Treatment Method
16.21.2.3. By Application
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Technology
17.3.3. By Treatment Method
17.3.4. By Application
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Advaxis Inc.
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Amgen Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Dynavax Technologies Corporation
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Generex Biotechnology Corporation
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. GlaxoSmithKline plc
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Immunocellular Therapeutics, Ltd
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Merck & Co., Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Vaccinogen, Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. F Hoffmann-La Roche AG
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. OSE Immunotherapeutics
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Cancer Vaccines Market
